|
1
|
McGuire S: World Cancer Report 2014.
Geneva, Switzerland: World Health Organization, International
Agency for Research on Cancer, WHO Press; 2015, Adv Nutr. 7. pp.
418–419. 2016, View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeng LP, Hu ZM, Li K and Xia K: miR-222
attenuates cisplatin-induced cell death by targeting the
PPP2R2A/Akt/mTOR Axis in bladder cancer cells. J Cell Mol Med.
20:559–567. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang X, Cheng Y, Li P, Tao J, Deng X,
Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21
diminishes aerobic glycolysis in bladder cancer T24 cells via the
PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–391. 2015. View Article : Google Scholar
|
|
6
|
Hanke M, Hoefig K, Merz H, Feller AC,
Kausch I, Jocham D, Warnecke JM and Sczakiel G: A robust
methodology to study urine microRNA as tumor marker: microRNA-126
and microRNA-182 are related to urinary bladder cancer. Urol Oncol.
28:655–661. 2010. View Article : Google Scholar
|
|
7
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
96(Suppl): R40–R44. 2007.PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vinall RL, Ripoll AZ, Wang S, Pan CX and
deVere White RW: miR-34a chemosensitizes bladder cancer cells to
cisplatin treatment regardless of p53-Rb pathway status. Int J
Cancer. 130:2526–2538. 2012. View Article : Google Scholar
|
|
11
|
Shen J, Zhang J, Xiao M, Yang J and Zhang
N: miR-203 suppresses bladder cancer cell growth and targets the
Twist1. Oncol Res. Sep 6–2017.(Epub ahead of print). doi:
10.3727/096504017X15041934685237.print) 2017. View Article : Google Scholar
|
|
12
|
Pop-Bica C, Gulei D, Cojocneanu-Petric R,
Braicu C, Petrut B and Berindan-Neagoe I: Understanding the role of
non-coding RNAs in bladder cancer: From dark matter to valuable
therapeutic targets. Int J Mol Sci. 18:182017. View Article : Google Scholar
|
|
13
|
Wei Z, Hu X, Liu J, Zhu W, Zhan X and Sun
S: MicroRNA-497 upregulation inhibits cell invasion and metastasis
in T24 and BIU-87 bladder cancer cells. Mol Med Rep. 16:2055–2060.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu D, Niu X, Tao J, Li P, Lu Q, Xu A, Chen
W and Wang Z: MicroRNA-379-5p plays a tumor-suppressive role in
human bladder cancer growth and metastasis by directly targeting
MDM2. Oncol Rep. 37:3502–3508. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Zhang Z, Li Z, Gong D, Zhan B,
Man X and Kong C: MicroRNA-497 inhibits the proliferation,
migration and invasion of human bladder transitional cell carcinoma
cells by targeting E2F3. Oncol Rep. 36:1293–1300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu H, Duan P, Zhu H and Rao D: miR-613
inhibits bladder cancer proliferation and migration through
targeting SphK1. Am J Transl Res. 9:1213–1221. 2017.PubMed/NCBI
|
|
17
|
Wu CL, Ho JY, Chou SC and Yu DS: miR-429
reverses epithelial-mesenchymal transition by restoring E-cadherin
expression in bladder cancer. Oncotarget. 7:26593–26603.
2016.PubMed/NCBI
|
|
18
|
Liu Y, Liu DL, Dong LL, Wen D, Shi DM,
Zhou J, Fan J and Wu WZ: miR-612 suppresses stem cell-like property
of hepatocellular carcinoma cells by modulating Sp1/Nanog
signaling. Cell Death Dis. 7:e23772016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tang J, Tao ZH, Wen D, Wan JL, Liu DL,
Zhang S, Cui JF, Sun HC, Wang L, Zhou J, et al: miR-612 suppresses
the stemness of liver cancer via Wnt/β-catenin signaling. Biochem
Biophys Res Commun. 447:210–215. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sheng L, He P, Yang X, Zhou M and Feng Q:
miR-612 negatively regulates colorectal cancer growth and
metastasis by targeting AKT2. Cell Death Dis. 6:e18082015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Umetsu SE, Shafizadeh N and Kakar S:
Grading and staging mucinous neoplasms of the appendix: A case
series and review of the literature. Hum Pathol. 69:81–89. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk–database: Prediction of possible miRNA binding sites by
'walking' the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dweep H and Gretz N: miRWalk2.0: A
comprehensive atlas of microRNA-target interactions. Nat Methods.
12:6972015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu H, Chen Y, Cheng S, Li G and Zhang Z:
Dysregulated expression of homebox gene HOXA13 is correlated with
the poor prognosis in bladder cancer. Wien Klin Wochenschr.
129:391–397. 2017. View Article : Google Scholar
|
|
25
|
Schenková K, Lutz J, Kopp M, Ramos S and
Rivero F: MUF1/leucine-rich repeat containing 41 (LRRC41), a
substrate of RhoBTB-dependent cullin 3 ubiquitin ligase complexes,
is a predominantly nuclear dimeric protein. J Mol Biol.
422:659–673. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng H, Li Q, Chen R, Zhang J, Ran Y, He
X, Li S and Shu HB: The dual-specificity phosphatase DUSP14
negatively regulates tumor necrosis factor- and
interleukin-1-induced nuclear factor-κB activation by
dephosphorylating the protein kinase TAK1. J Biol Chem.
288:819–825. 2013. View Article : Google Scholar
|
|
27
|
Mukhtar YM, Huang Y, Liu J, Chen D and
Zheng W: Acetanilide and bromoacetyl-lysine derivatives as
activators for human histone deacetylase 8. Bioorg Med Chem Lett.
27:2319–2323. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sengupta S, Weeraratne SD, Sun H, Phallen
J, Rallapalli SK, Teider N, Kosaras B, Amani V, Pierre-Francois J,
Tang Y, et al: α5-GABAA receptors negatively regulate MYC-amplified
medulloblastoma growth. Acta Neuropathol. 127:593–603. 2014.
View Article : Google Scholar
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Braicu C, Cojocneanu-Petric R, Chira S,
Truta A, Floares A, Petrut B, Achimas-Cadariu P and Berindan-Neagoe
I: Clinical and pathological implications of miRNA in bladder
cancer. Int J Nanomedicine. 10:791–800. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoshino H, Seki N, Itesako T, Chiyomaru T,
Nakagawa M and Enokida H: Aberrant expression of microRNAs in
bladder cancer. Nat Rev Urol. 10:396–404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hu Y, Cheng C, Hong Z and Shi Z:
Independent prognostic miRNAs for bladder urothelial carcinoma.
Oncol Lett. 14:3001–3005. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu X, Liu X, Wu Y, Wu Q, Wang Q, Yang Z
and Li L: MicroRNAs in biofluids are novel tools for bladder cancer
screening. Oncotarget. 8:32370–32379. 2017.PubMed/NCBI
|
|
34
|
Wang X, Liang Z, Xu X, Li J, Zhu Y, Meng
S, Li S, Wang S, Xie B, Ji A, et al: miR-148a-3p represses
proliferation and EMT by establishing regulatory circuits between
ERBB3/AKT2/c-myc and DNMT1 in bladder cancer. Cell Death Dis.
7:e25032016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiang P, Du W, Mancuso A, Wellen KE and
Yang X: Reciprocal regulation of p53 and malic enzymes modulates
metabolism and senescence. Nature. 493:689–693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wen D, Liu D, Tang J, Dong L, Liu Y, Tao
Z, Wan J, Gao D, Wang L, Sun H, et al: Malic enzyme 1 induces
epithelial-mesenchymal transition and indicates poor prognosis in
hepatocellular carcinoma. Tumour Biol. 36:6211–6221. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shen H, Xing C, Cui K and Li Y, Zhang J,
Du R, Zhang X and Li Y: MicroRNA-30a attenuates mutant KRAS-driven
colorectal tumorigenesis via direct suppression of ME1. Cell Death
Differ. 24:1253–1262. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chakrabarti G: Mutant KRAS associated
malic enzyme 1 expression is a predictive marker for radiation
therapy response in non-small cell lung cancer. Radiat Oncol.
10:1452015. View Article : Google Scholar : PubMed/NCBI
|
